Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice.
OBJECTIVE
To investigate the efficacy and safety outcomes of combination therapy used to optimize etanercept treatment in patients with psoriasis treated in real-life clinical practice.


METHODS
Data from patients presenting with psoriasis, treated initially with etanercept monotherapy, were analysed retrospectively. Patients subsequently treated with combination therapy were further analysed. The Psoriasis Area and Severity Index (PASI) score was recorded for all patients receiving comedication; a subjective pain score was recorded in those with psoriatic arthritis receiving comedication after 12, 24 and 48 weeks' treatment and thereafter at 6-month intervals.


RESULTS
From the database of 400 patients treated with etanercept, 37 patients (18 male; 19 female; mean age 59.43 years) underwent combination therapy due to lack of efficacy. Patients received mostly short-term (range 4-34 weeks) comedication with corticosteroids, cyclosporine, methotrexate, nonsteroidal anti-inflammatory drugs, acitretin or sulphasalazine. There were significant reductions in the mean PASI score from baseline at all timepoints. There were also significant reductions in the mean pain VAS score from baseline at all timepoints in patients with psoriatic arthritis. The drug survival rate was 59.6% over a mean duration of 323 weeks of etanercept treatment. The safety profile of combination therapy was satisfactory.


CONCLUSIONS
Short-term comedication in combination with etanercept may optimize treatment options and improve long-term drug survival in patients with psoriasis.
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Graziella
G
Babino
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Alessandro
A
Giunta
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Manuela
M
Ruzzetti
Rheumatology, Allergology and Clinical Immunology, Department of Systemic Medicine, University of Tor Vergata, Rome, Italy.
Maria
M
Sole Chimenti
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Sergio
S
Chimenti
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy espositomaria@virgilio.it.
Maria
M
Esposito
Comedication; etanercept; psoriasis; tumour necrosis factor-α antagonists
Br J Dermatol. 2009 Mar;160(3):670-5
19210502
Am J Clin Dermatol. 2005;6(6):383-92
16343026
Arch Dermatol Res. 2011 Jan;303(1):1-10
20857129
J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):434-44
15761421
Am J Clin Dermatol. 2014 Dec;15(6):467-78
25373522
Dermatologica. 1978;157(4):238-44
357213
Br J Dermatol. 2013 Sep;169(3):666-72
23647206
J Eur Acad Dermatol Venereol. 2014 Apr;28(4):438-53
23437792
J Eur Acad Dermatol Venereol. 2009 Oct;23 Suppl 2:1-70
19712190
Acta Derm Venereol. 2010 Jul;90(4):341-9
20574597
Arthritis Rheum. 2006 Aug;54(8):2665-73
16871531